Weight-loss medications like Ozempic and Wegovy have been under discussion for some time, but new research suggests there may be better alternatives. Enter Amicretin, a novel weight-loss treatment available in pill form rather than injection.
In the initial human trials of this new weight loss medication, the developer Novo Nordisk A/S (the company behind Ozempic) saw promising results: participants taking Amicretin lost an average of 13.1 percent of their body weight over a 12-week period.
So, how does this new weight loss pill function? Amicretin is a dual-acting drug that emulates the effects of two hormones crucial in weight loss: amylin and glucagon-like peptide-1 (GLP-1), which help curb hunger and regulate appetite.
Published in the journal Diabetology, the study compared average weight loss in three groups with BMIs between 25 and 39.9 who did not have diabetes.
By the end of the 12-week study, subjects taking two 50 mg tablets of Amicretin lost 13.1% of their body weight, compared to 10.4% in those taking one 50 mg tablet. In contrast, the placebo group only lost an average of 1.1% of their body weight throughout the study.
Compared to other weight loss drugs, a recent study in JAMA Internal Medicine found that patients taking another weight-loss drug, Maunjaro, lost 5.9% body fat in 3 months, while those on Ozempic saw a decrease of 3.6%.
“The difference from injectable treatments is significant,” states obesity expert Christopher Clemmensen. “The dual mode of action offers promise, making Amicretin a valuable advancement for Novo Nordisk.”
While weight-loss drugs show promise in combating obesity worldwide, further confirmation awaits larger trials on individuals with chronic conditions. Professor Navid Sattar emphasizes the importance of developing safe and accessible medications for the millions suffering from obesity.
Excitement surrounds this early-stage study of a novel oral weight-loss medication combination due to its rapid effects on body weight.
About our experts
Associate Professor Christopher Clemmensen leads the Clemmensen Group at the University of Copenhagen, studying biological weight regulation and developing obesity treatment strategies. His research appears in respected publications such as Natural Metabolism and Molecular Metabolism.
Read more:
Source: www.sciencefocus.com
